Corrigendum to 'Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival': [Annals of Oncology Volume 32, Issue 8, August 2021, Pages 1015-1024]

Affiliations

¹ David Geffen School of Medicine at UCLA, Los Angeles, USA. Electronic address: dslamon@mednet.ucla.edu.
² Multidisciplinary Breast Centre, Universitair Ziekenhuis Leuven, Leuven, Belgium.
³ British Columbia Cancer Agency, Vancouver, Canada.
⁴ CHU Liege and Liège University, Liège, Belgium.
⁵ Istituto Nazionale Tumori IRCCS 'Fondazione G. Pascale', Naples, Italy.
⁶ Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine, Seoul, Republic of Korea.
⁷ Masaryk Memorial Cancer Institute, Brno, Czech Republic.
⁸ Fondazione Istituto di Ricovero e Cura a Carattere Scientifico, Istituto Nazionale dei Tumori, Milan, Italy.
⁹ Instituto de Investigación Sanitaria Gregorio Marañon, Centro de Investigación Biomédica en Red de Cáncer, Grupo Español de Investigación en Cáncer de Mama, Universidad Complutense, Madrid, Spain.
¹⁰ Practice for Hematology and Internal Oncology, Velbert, Germany.
¹¹ Netherlands Cancer Institute/Borstkanker Onderzoek Groep Study Center, Amsterdam, The Netherlands.
¹² Hospital Universitario Virgen Macarena, Seville, Spain.
¹³ Highlands Oncology Group, Fayetteville, USA.
¹⁴ Novartis Pharmaceuticals Corporation, East Hanover, USA.
¹⁵ Novartis Pharma AG, Basel, Switzerland.
¹⁶ Department of Gynecology and Obstetrics, University Hospital Erlangen, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen, Erlangen, Germany.

Free article

Published Erratum

D J Slamon et al. Ann Oncol. 2021 Oct.

Free article

. 2021 Oct;32(10):1307.

doi: 10.1016/j.annonc.2021.07.011. Epub 2021 Aug 16.

¹ David Geffen School of Medicine at UCLA, Los Angeles, USA. Electronic address: dslamon@mednet.ucla.edu.
² Multidisciplinary Breast Centre, Universitair Ziekenhuis Leuven, Leuven, Belgium.
³ British Columbia Cancer Agency, Vancouver, Canada.
⁴ CHU Liege and Liège University, Liège, Belgium.
⁵ Istituto Nazionale Tumori IRCCS 'Fondazione G. Pascale', Naples, Italy.
⁶ Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine, Seoul, Republic of Korea.
⁷ Masaryk Memorial Cancer Institute, Brno, Czech Republic.
⁸ Fondazione Istituto di Ricovero e Cura a Carattere Scientifico, Istituto Nazionale dei Tumori, Milan, Italy.
⁹ Instituto de Investigación Sanitaria Gregorio Marañon, Centro de Investigación Biomédica en Red de Cáncer, Grupo Español de Investigación en Cáncer de Mama, Universidad Complutense, Madrid, Spain.
¹⁰ Practice for Hematology and Internal Oncology, Velbert, Germany.
¹¹ Netherlands Cancer Institute/Borstkanker Onderzoek Groep Study Center, Amsterdam, The Netherlands.
¹² Hospital Universitario Virgen Macarena, Seville, Spain.
¹³ Highlands Oncology Group, Fayetteville, USA.
¹⁴ Novartis Pharmaceuticals Corporation, East Hanover, USA.
¹⁵ Novartis Pharma AG, Basel, Switzerland.
¹⁶ Department of Gynecology and Obstetrics, University Hospital Erlangen, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen, Erlangen, Germany.

No abstract available

Erratum for

Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival.
Slamon DJ, Neven P, Chia S, Jerusalem G, De Laurentiis M, Im S, Petrakova K, Valeria Bianchi G, Martín M, Nusch A, Sonke GS, De la Cruz-Merino L, Beck JT, Ji Y, Wang C, Deore U, Chakravartty A, Zarate JP, Taran T, Fasching PA. Slamon DJ, et al. Ann Oncol. 2021 Aug;32(8):1015-1024. doi: 10.1016/j.annonc.2021.05.353. Epub 2021 Jun 5. Ann Oncol. 2021. PMID: 34102253 Clinical Trial.